Nanobiotix S.A. (NBTX)
| Market Cap | 538.78M |
| Revenue (ttm) | 3.06M |
| Net Income (ttm) | -40.96M |
| Shares Out | 34.43M |
| EPS (ttm) | -1.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $15.65 |
| Previous Close | $16.08 |
| Change ($) | -0.43 |
| Change (%) | -2.66% |
| Day's Open | 15.96 |
| Day's Range | 15.31 - 15.65 |
| Day's Volume | 3,117 |
| 52-Week Range | 12.85 - 21.55 |
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company'') (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneerin...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company'), a late-stage clinical biotechnology company pioneeri...
Nanobiotix (NASDAQ: NBTX) and PharmaEngine Inc have agreed to terminate the license and collaboration agreement announced in August 2012. The agreement provided PharmaEngine exclusive rights to further ...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based approaches to ...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering p...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #NBTXR3--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based appr...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #cancer--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based appro...
NBTXR3 has shown significant ability to improve effectiveness of radiotherapy in clinical studies. Approximately 60% of all cancer patients receive some for of radiotherapy.
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #NBTXR3--Regulatory News: “We believe that NBTXR3 could have a positive impact for patients with cancer in any case where radiotherapy is a part of the standa...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #NBTX--NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing f...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing first-in-class prod...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company”), a clinical-stage biotechnology company focused on developing first-in-c...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing first-in-class product ...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to ...
PARIS--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to the treatme...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approac...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approac...
About NBTX
Nanobiotix is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use our proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. Our lead product candidate, NBTXR3, is an aqueous suspension of functionalized crystalline hafnium oxide nanoparticles designed for injection directly into a malignant tumor prior to standard radiotherapy. When exposed to ionizing radiation, NBTXR3 amplifies the localized, intratumor killing effect of that radiation and may a... [Read more...]
| Industry Biotechnology | IPO Date Dec 11, 2020 |
| CEO Laurent Levy | Employees 88 |
| Stock Exchange NASDAQ | Ticker Symbol NBTX |
Financial Performance
In 2020, Nanobiotix's revenue was 2.51 million, a decrease of -1.14% compared to the previous year's 2.54 million. Losses were -33.59 million, -34.03% less than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for Nanobiotix is 24.80, which is an increase of 58.47% from the latest price.